Given the body of evidence demonstrating the protective role of H2S against atherosclerosis, reperfusion injury, cardiomyopathy, hypertension and other cardiovascular diseases [[291], [292], [293], [294], [295], [296]], the question if treatment with CBS inhibitor may increase the risk of cardiovascular events in DS individuals should also be considered. The gene discussed is CBS; the disease is Dravet syndrome.